<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02760576</url>
  </required_header>
  <id_info>
    <org_study_id>18612</org_study_id>
    <nct_id>NCT02760576</nct_id>
  </id_info>
  <brief_title>18612 - Sun Protection Factor Assay</brief_title>
  <official_title>Sun Protection Factor (SPF) Assay: UVA Protection Factor Assay on Minimal Persistent Pigment-Darkening Dose</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the Sun Protection Factor efficacy on human skin.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 14, 2015</start_date>
  <completion_date type="Actual">October 16, 2015</completion_date>
  <primary_completion_date type="Actual">October 16, 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Minimal Erythema Dose (MED)</measure>
    <time_frame>Up to 15 minutes</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Minimal Persistent Pigment Darkening Dose (MPPD)</measure>
    <time_frame>Up to 15 minutes</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Sunscreening Agents</condition>
  <arm_group>
    <arm_group_label>BAY 987521</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BAY 987521</intervention_name>
    <description>Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.</description>
    <arm_group_label>BAY 987521</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Fitzpatrick Skin Type l, ll and/or lll for UVB testing; Fitzpatrick Skin Type ll, lll
             and/or lV for UVA testing.

          -  Male and female.

          -  Aged between 18-70 years old.

          -  Good health as determined from the HRL SHF (Subject History Form).

          -  Signed and dated Informed Consent Form.

          -  Signed and dated HIPAA Form (Health Insurance Portability and Accountability Act).

          -  An unambiguous MED (Minimal Erythema Dose) or MPPD (Minimal Persistent Pigment
             Darkening Dose).

        Exclusion Criteria:

          -  Known allergy or sensitivity to sunscreens, cosmetics and toiletries, topical drugs
             and/or ultraviolet light.

          -  Pre-existing dermatologic conditions which have been diagnosed by a medical
             professional (e.g. psoriasis, eczema, etc.) which would interfere with this study.

          -  Pre-existing other medical conditions (e.g. adult asthma, diabetes).

          -  Treatment with antihistamines or corticosteroids within one week prior to initiation
             of the test.

          -  Treatment with antibiotics within two weeks prior to initiation of the test.

          -  Chronic medication which could affect the results of the study.

          -  Known pregnant or nursing women.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Union</city>
        <state>New Jersey</state>
        <zip>07083</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>May 2, 2016</study_first_submitted>
  <study_first_submitted_qc>May 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 3, 2016</study_first_posted>
  <last_update_submitted>December 11, 2018</last_update_submitted>
  <last_update_submitted_qc>December 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

